Table 4.
Detection of Ipsilateral and Contralateral Breast Cancers in Women With a Personal History of Breast Cancer
| Detection of Ipsilateral Cancers (n = 258) |
Detection of Contralateral Cancers (n = 333) |
|||
|---|---|---|---|---|
| No./Totala | Sensitivity (95% CI) |
No./Totala | Sensitivity (95% CI) |
|
| Overall screening mammography sensitivity | 171/258 | 66.3 (60.3–71.8) | 220/333 | 66.1 (60.9–70.9) |
| Age at mammography, y | ||||
| <50 | 34/60 | 56.7 (44.0–68.5) | 18/41 | 43.9 (29.7–59.2)b |
| 50–59 | 47/76 | 61.8 (50.5–72.0) | 43/66 | 65.2 (53.0–75.6)b |
| 60–69 | 36/47 | 76.6 (62.5–86.5) | 52/72 | 72.2 (61.0–81.2)b |
| ≥70 | 54/75 | 72.0 (61.0–80.9) | 107/154 | 69.5 (61.9–76.2)b |
| BI-RADS breast density | ||||
| 1, Almost entirely fatty | 4/5 | 80.0 (NC)c | 7/9 | 77.8 (NC)c |
| 2, Scattered fibroglandular tissue | 66/93 | 71.0 (60.8–79.4) | 75/108 | 69.4 (60.2–77.3) |
| 3, Heterogeneously dense | 51/86 | 59.3 (48.7–69.1) | 69/109 | 63.3 (54.1–71.7) |
| 4, Extremely dense | 11/16 | 68.8 (43.3–86.4) | 10/22 | 45.5 (26.5–65.9) |
| Time since last mammogram, mo | ||||
| 9–14 | 124/197 | 62.9 (56.0–69.4) | 178/269 | 66.2 (60.4–71.5) |
| 15–23 | 27/37 | 73.0 (56.7–84.8) | 26/38 | 68.4 (52.2–81.1) |
| ≥24 | 10/13 | 76.9 (47.8–92.4) | 14/23 | 60.9 (40.2–78.2) |
| Time since first breast cancer diagnosis, y | ||||
| <1 | 17/22 | 77.3 (55.6–90.2) | 14/24 | 58.3 (38.3–75.9)b |
| 1–2 | 34/57 | 59.6 (46.5–71.5) | 39/66 | 59.1 (46.9–70.2)b |
| 3–4 | 45/69 | 65.2 (53.3–75.5) | 35/64 | 54.7 (42.6–66.2)b |
| 5–6 | 33/43 | 76.7 (61.9–87.0) | 53/70 | 75.7 (64.4–84.3)b |
| 7–9 | 25/42 | 59.5 (44.6–72.8) | 45/67 | 67.2 (55.3–77.2)b |
| ≥10 | 17/25 | 68.0 (47.8–83.1) | 34/42 | 81.0 (66.3–90.2)b |
| Type of first breast cancer | ||||
| Ductal carcinoma in situ | 83/112 | 74.1 (65.2–81.4)b | 52/72 | 72.2 (60.8–81.3) |
| Invasive cancer | 88/146 | 60.3 (52.1–67.9)b | 168/261 | 64.4 (58.4–69.9) |
| Primary surgery | ||||
| Breast conserving without radiation | 55/83 | 66.3 (55.5–75.6) | 29/48 | 60.4 (46.1–73.1) |
| Breast conserving with radiation | 99/154 | 64.3 (56.4–71.5) | 108/165 | 65.5 (57.9–72.3) |
| Mastectomy | NA | NA | 75/110 | 68.2 (59.1–76.1) |
| Radiation therapy | ||||
| None | 55/83 | 66.3 (55.5–75.6) | 85/131 | 64.9 (56.4–72.5) |
| Any | 99/154 | 64.3 (56.4–71.5) | 128/194 | 66.0 (59.1–72.2) |
| Adjuvant systemic therapy | ||||
| None | 110/153 | 71.9 (64.3–78.4)b | 130/180 | 72.2 (65.3–78.2)b |
| Any, chemotherapy or endocrine | 40/78 | 51.3 (40.2–62.3)b | 74/131 | 56.5 (48.0–64.6)b |
| Self-reported history of breast implant, reduction, or reconstruction | ||||
| No | 119/181 | 65.7 (58.5–72.3) | 152/227 | 67.0 (60.6–72.7) |
| Yes | 2/3 | 66.7 (NC)c | 7/16 | 43.8 (22.5–67.6) |
Abbreviations: BI-RADS, Breast Imaging Reporting and Data System; CI, confidence interval; NA, not applicable.
a
Numberof screen-detected cancers (ie, positive screen results associated with ipsilateral or contralateral cancer during followup) and total number of cancers observed at 12mo(ie, number of screens associated with ipsilateral or contralateral cancer during follow-up). For each variable, total in columns may not equal the overall total because of missing data.
b
P<.05, based on score statistics obtained in generalized estimating equation analyses.
c
Not calculated (NC) if fewer than 10 events